Does the Serum-Amyloid-A to High-Density-Lipoprotein-Cholesterol Ratio (SHR) improve the early diagnosis of CAD with clinically relevant stenoses compared to CRP and SAA?
The Serum-Amyloid-A to High-Density-Lipoprotein-Cholesterol Ratio (SHR), especially when integrated into a machine learning model, offers a promising new strategy for the early screening of clinically relevant coronary artery disease.
SHR is a superior composite biomarker for early diagnosis of CAD with clinically relevant stenoses, outperforming CRP and SAA. Machine learning model integrating multiple indicators shows excellent diagnostic performance. Elevated SHR indicates higher CAD risk in younger individuals, providing a new strategy for early screening of CAD with clinically relevant stenoses.
Wang et al. (Fri,) studied this question.